Labcorp Holdings (LH) Stock Overview
Provides laboratory services. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
LH Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Labcorp Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$284.39 |
| 52 Week High | US$293.72 |
| 52 Week Low | US$241.81 |
| Beta | 0.86 |
| 1 Month Change | 7.26% |
| 3 Month Change | 5.65% |
| 1 Year Change | 10.28% |
| 3 Year Change | 35.12% |
| 5 Year Change | 1.04% |
| Change since IPO | 1,066.73% |
Recent News & Updates
Narrative Update • Jun 16
LH: AI Health Platform And Testing Expansion Will Support Long Term Upside
Analysts have kept their price target for Labcorp Holdings steady at about $310, with only marginal tweaks to assumptions for discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall valuation view. What’s in the News for Labcorp Holdings Collaboration with the Alliance for Clinical Trials in Oncology to run a national colorectal cancer trial, using Labcorp’s Invitae testing as the exclusive genetic testing platform and focusing on broader germline and multigene panel testing adoption.Narrative Update • Jun 02
LH: AI And New Diagnostics Collaborations Will Support Long Term Upside
Labcorp Holdings’ analyst price target has been adjusted slightly higher to approximately $310 per share as analysts refine their assumptions around the discount rate, revenue growth, profit margin and future P/E to reflect updated views on the company’s long-term earnings potential. What's in the News Q1 2026 results show revenue of US$3.54b, up 5.8% year over year, and adjusted EPS of US$4.25, up 10.6%, with management raising full year 2026 revenue guidance to 5.0% to 6.1% growth and adjusted EPS guidance to US$17.70 to US$18.35 (source: Q1 2026 earnings release).Recent updates
Narrative Update • Jun 16
LH: AI Health Platform And Testing Expansion Will Support Long Term Upside
Analysts have kept their price target for Labcorp Holdings steady at about $310, with only marginal tweaks to assumptions for discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall valuation view. What’s in the News for Labcorp Holdings Collaboration with the Alliance for Clinical Trials in Oncology to run a national colorectal cancer trial, using Labcorp’s Invitae testing as the exclusive genetic testing platform and focusing on broader germline and multigene panel testing adoption.Narrative Update • Jun 02
LH: AI And New Diagnostics Collaborations Will Support Long Term Upside
Labcorp Holdings’ analyst price target has been adjusted slightly higher to approximately $310 per share as analysts refine their assumptions around the discount rate, revenue growth, profit margin and future P/E to reflect updated views on the company’s long-term earnings potential. What's in the News Q1 2026 results show revenue of US$3.54b, up 5.8% year over year, and adjusted EPS of US$4.25, up 10.6%, with management raising full year 2026 revenue guidance to 5.0% to 6.1% growth and adjusted EPS guidance to US$17.70 to US$18.35 (source: Q1 2026 earnings release).Narrative Update • May 18
LH: Expanded Epic Integration And New Diagnostics Will Support Long Term Upside
Analysts have kept their $310.06 price target for Labcorp Holdings steady, citing only modest tweaks to assumptions, such as a slightly higher discount rate, marginally adjusted revenue growth and profit margin forecasts, and a small change in expected future P/E that together do not materially shift their overall valuation view. What's in the News Expanded collaboration with Epic will make Labcorp's full test menu available through Aura, Epic's platform for ordering and receiving lab results.Analysis Article • May 07
Labcorp Holdings Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
As you might know, Labcorp Holdings Inc. ( NYSE:LH ) recently reported its first-quarter numbers. The result was...Narrative Update • May 02
LH: Expanded Diagnostics And AI Platforms Will Support Long Term Upside
Analysts have lifted their price target on Labcorp Holdings to $310, citing slightly higher revenue growth expectations, a firmer profit margin outlook and a lower future P/E assumption as key factors behind the revised view. What's in the News Launched nationwide access to Agilent's FDA approved PD-L1 IHC 22C3 pharmDx companion diagnostic to identify patients with platinum resistant ovarian cancer who may be eligible for Merck's KEYTRUDA based regimens, following early participation in Agilent's validation program (Key Developments).Narrative Update • Apr 17
LH: Expanded Cancer And Alzheimer’s Platforms Will Support Long Term Upside
Analysts have adjusted their price target on Labcorp Holdings slightly higher to $310, citing modest updates to fair value estimates, revenue growth assumptions, future P/E expectations, and a small change in projected profit margins. What's in the News Launched the Labcorp Fentanyl Urine Visual Test, the first FDA cleared rapid fentanyl urine test of its kind manufactured in the US, delivering results in about 10 minutes for use in CLIA certified acute care and clinical settings (Key Developments).Narrative Update • Apr 02
LH: Expanded Cancer And Alzheimer’s Testing Will Support Future Upside
Analysts kept their average price target for Labcorp Holdings steady at about $307.71. This reflects unchanged views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions.Narrative Update • Mar 18
LH: Alzheimer’s And Cancer Testing Expansion And Buybacks Will Support Upside Outlook
Analysts have made a small upward adjustment to their price target for Labcorp Holdings, lifting it by about $0.06 as they fine tune inputs such as expected revenue growth, profit margin, discount rate, and future P/E assumptions. What's in the News Issued full year 2026 earnings guidance with expected revenue in a range of US$14.61b to US$14.79b, with midpoint revenue growth of 5.4%.Narrative Update • Mar 03
LH: Alzheimer’s And Cancer Testing And Buybacks Will Support Steady Outlook
Analysts have adjusted their price target on Labcorp Holdings to $307.65 from $300.18, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E expectations. What's in the News Issued full year 2026 earnings guidance, with expected revenue in a range of $14.61b to $14.79b and a midpoint growth figure of 5.4% (company guidance).Narrative Update • Feb 17
LH: Alzheimer’s And Cancer Testing Advances Will Support Balanced Future Outlook
Analysts have inched their price target for Labcorp Holdings slightly higher to about $300.18 per share from roughly $300.06. This change reflects small adjustments to their fair value model inputs, including discount rate, revenue growth, profit margin, and future P/E assumptions.Analysis Article • Feb 11
Labcorp Holdings (NYSE:LH) Has Announced A Dividend Of $0.72
Labcorp Holdings Inc.'s ( NYSE:LH ) investors are due to receive a payment of $0.72 per share on 12th of March. This...Narrative Update • Feb 03
LH: MRD And AI Oncology Advances Will Support Balanced Future Outlook
Analysts have kept their price target for Labcorp Holdings essentially unchanged at about US$300, reflecting only minimal tweaks to assumptions on discount rate, revenue growth, profit margin, and future P/E estimates. What's in the News Labcorp expanded its molecular residual disease portfolio with Plasma Detect ID for stage I to IIIA non small cell lung cancer and nationwide Plasma Detect Genome MRD testing for stage III colon cancer, both designed to detect circulating tumor DNA at very low levels to support earlier insight into cancer recurrence risk.Narrative Update • Jan 20
LH: AI Oncology And Alzheimer’s Testing Will Support Balanced Future Outlook
Analysts have inched up their price target on Labcorp Holdings to about US$300 per share. This reflects updated assumptions around slightly higher revenue growth, a modestly adjusted profit margin profile, and a similar forward P/E multiple.Analysis Article • Jan 17
Labcorp Holdings' (NYSE:LH) Dividend Will Be $0.72
Labcorp Holdings Inc.'s ( NYSE:LH ) investors are due to receive a payment of $0.72 per share on 12th of March. This...Narrative Update • Jan 06
LH: AI Oncology Diagnostics Will Support Future Upside Potential
Analysts have reaffirmed their projected fair value for Labcorp Holdings at about US$300 per share, citing only very small tweaks to assumptions around discount rate, revenue growth, profit margins and future P/E that leave their overall price target effectively unchanged. What's in the News Labcorp Plasma Detect, a tumor informed blood test for molecular residual disease, was featured in peer reviewed studies in Nature Medicine and Clinical Cancer Research.Narrative Update • Dec 14
LH: AI Cancer Diagnostics And Share Repurchases Will Drive Future Upside
Analysts have modestly reaffirmed their outlook on Labcorp Holdings, maintaining the price target effectively unchanged at approximately $300 per share. They continue to see a stable balance of revenue growth, profit margins, and valuation multiples.Narrative Update • Nov 29
LH: Share Buybacks And AI-Powered Cancer Detection Will Drive Long-Term Upside
Analysts have slightly lowered their price target for Labcorp Holdings from $300.12 to $299.71, citing small adjustments to profit margin and future growth expectations. What's in the News Labcorp Plasma Detect, a blood-based assay for detecting molecular residual disease, was featured in peer-reviewed publications for its potential in early cancer progression tracking and improving treatment strategies for rare cancers.Analysis Article • Nov 19
Labcorp Holdings (NYSE:LH) Will Pay A Dividend Of $0.72
Labcorp Holdings Inc. ( NYSE:LH ) will pay a dividend of $0.72 on the 11th of December. This payment means the dividend...Narrative Update • Nov 14
LH: Share Repurchases And Expanded Alzheimer’s Testing Will Drive Future Upside
Narrative Update: Labcorp Holdings Analyst Price Target Adjustment Analysts have raised their price target for Labcorp Holdings by $1. This change reflects a marginally improved outlook based on updated fair value and company fundamentals.Analysis Article • Nov 07
The Strong Earnings Posted By Labcorp Holdings (NYSE:LH) Are A Good Indication Of The Strength Of The Business
Even though Labcorp Holdings Inc. ( NYSE:LH ) posted strong earnings, investors appeared to be underwhelmed. We have...Narrative Update • Oct 31
LH: Share Repurchases And Alzheimer’s Test Launch Will Drive Profits Ahead
Analysts have modestly raised their price target for Labcorp Holdings from $296.18 to $299.12. They cite solid improvements in projected profit margins, which offset slightly lower top-line growth expectations.Analysis Article • Oct 31
The Labcorp Holdings Inc. (NYSE:LH) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
It's been a sad week for Labcorp Holdings Inc. ( NYSE:LH ), who've watched their investment drop 11% to US$252 in the...Analysis Article • Oct 28
Labcorp Holdings (NYSE:LH) Will Pay A Dividend Of $0.72
Labcorp Holdings Inc. ( NYSE:LH ) has announced that it will pay a dividend of $0.72 per share on the 11th of December...Narrative Update • Oct 17
AI And Collaborations Will Transform Diagnostic Testing
Analysts have modestly raised their price target for Labcorp Holdings to $296.18 from $294.65. They cite incremental improvements in revenue growth projections, despite a slight dip in estimated profit margin.Analysis Article • Oct 12
Labcorp Holdings (NYSE:LH) Is Due To Pay A Dividend Of $0.72
Labcorp Holdings Inc. ( NYSE:LH ) has announced that it will pay a dividend of $0.72 per share on the 11th of December...Narrative Update • Oct 03
AI And Collaborations Will Transform Diagnostic Testing
Labcorp Holdings' analyst price target has been revised upward from $293.76 to $294.65. This modest increase is attributed by analysts to slight improvements in projected revenue growth and future valuation metrics.Seeking Alpha • Sep 17
Labcorp Holdings: Currently Priced For Cash And Growth
Summary Labcorp Holdings has rallied 27% on multiple expansion, but growth prospects remain moderate and capital intensity is rising. Q2 results showed solid revenue and margin gains, with raised guidance, strong cash generation, and biopharma backlog growth, yet core returns lag expectations. LH's valuation reflects premium pricing for durability and moderate growth, but current returns on invested capital and NOPAT yield are below ideal levels. Reiterate Hold rating: at ~$250/share fair value, current multiples price in growth that is unlikely to materialize, making it early to buy LH in size. Read the full article on Seeking AlphaAnalysis Article • Sep 16
Investors Interested In Labcorp Holdings Inc.'s (NYSE:LH) Earnings
With a price-to-earnings (or "P/E") ratio of 30x Labcorp Holdings Inc. ( NYSE:LH ) may be sending very bearish signals...Analysis Article • Aug 19
Labcorp Holdings (NYSE:LH) Will Pay A Dividend Of $0.72
Labcorp Holdings Inc. ( NYSE:LH ) will pay a dividend of $0.72 on the 11th of September. This payment means the...Analysis Article • Jul 30
Labcorp Holdings (NYSE:LH) Is Paying Out A Dividend Of $0.72
The board of Labcorp Holdings Inc. ( NYSE:LH ) has announced that it will pay a dividend of $0.72 per share on the 11th...Analysis Article • Jul 13
Labcorp Holdings (NYSE:LH) Has Affirmed Its Dividend Of $0.72
Labcorp Holdings Inc. ( NYSE:LH ) has announced that it will pay a dividend of $0.72 per share on the 11th of...Seeking Alpha • Apr 17
Labcorp Holdings: Regaining Credibility
Summary Labcorp's shares have shown modest returns over the past year as organic growth and bolt-on M&A act as drivers for the business going forward. The company made several strategic acquisitions, including BioReference Health and Invitae assets, boosting sales and adjusted earnings, while maintaining a reasonable valuation. Despite solid growth and modest deleveraging, long-term concerns about AI disrupting legacy testing methods make me cautious about the business's future. Overall, LH's shares are fairly valued, with steady growth and strategic acquisitions, but potential AI disruption warrants a balanced investment approach. Read the full article on Seeking AlphaShareholder Returns
| LH | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 1.7% | 2.0% | 1.6% |
| 1Y | 10.3% | 28.7% | 18.6% |
Return vs Industry: LH underperformed the US Healthcare industry which returned 28.7% over the past year.
Return vs Market: LH underperformed the US Market which returned 18.6% over the past year.
Price Volatility
| LH volatility | |
|---|---|
| LH Average Weekly Movement | 3.3% |
| Healthcare Industry Average Movement | 7.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: LH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LH's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 66,385 | Adam Schechter | www.labcorp.com |
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests.
Labcorp Holdings Inc. Fundamentals Summary
| LH fundamental statistics | |
|---|---|
| Market cap | US$23.53b |
| Earnings (TTM) | US$941.50m |
| Revenue (TTM) | US$14.14b |
24.8x
P/E Ratio1.6x
P/S RatioIs LH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LH income statement (TTM) | |
|---|---|
| Revenue | US$14.14b |
| Cost of Revenue | US$10.07b |
| Gross Profit | US$4.08b |
| Other Expenses | US$3.14b |
| Earnings | US$941.50m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 30, 2026
| Earnings per share (EPS) | 11.48 |
| Gross Margin | 28.83% |
| Net Profit Margin | 6.66% |
| Debt/Equity Ratio | 73.0% |
How did LH perform over the long term?
See historical performance and comparisonDividends
1.0%
Current Dividend Yield25%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 22:32 |
| End of Day Share Price | 2026/07/06 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Labcorp Holdings Inc. is covered by 40 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Eric Coldwell | Baird |
| Adam Feinstein | Barclays |